Healthcare of Ontario Pension Plan Trust Fund Has $32.67 Million Holdings in GSK plc (NYSE:GSK)

Healthcare of Ontario Pension Plan Trust Fund cut its position in GSK plc (NYSE:GSK) by 41.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 799,200 shares of the pharmaceutical company’s stock after selling 564,100 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund’s holdings in GSK were worth $32,671,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Eastern Bank acquired a new stake in GSK in the 3rd quarter worth $26,000. Concord Wealth Partners grew its position in GSK by 231.8% in the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock worth $32,000 after purchasing an additional 547 shares during the last quarter. Ashton Thomas Private Wealth LLC acquired a new stake in GSK in the 2nd quarter worth $37,000. Fortitude Family Office LLC acquired a new stake in GSK in the 3rd quarter worth $42,000. Finally, PrairieView Partners LLC acquired a new stake in GSK in the 2nd quarter worth $47,000. 15.74% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at GSK

In related news, major shareholder Plc Gsk bought 2,791,930 shares of the company’s stock in a transaction on Friday, September 27th. The stock was bought at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the purchase, the insider now owns 16,775,691 shares in the company, valued at approximately $134,205,528. The trade was a 19.97 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 10.00% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on GSK shares. Argus upgraded shares of GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. Barclays raised shares of GSK to a “hold” rating in a report on Tuesday, August 27th. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Finally, Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Seven analysts have rated the stock with a hold rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Trading Up 0.9 %

Shares of GSK stock opened at $34.32 on Thursday. GSK plc has a 12-month low of $32.83 and a 12-month high of $45.92. The company has a market capitalization of $71.13 billion, a P/E ratio of 22.29, a P/E/G ratio of 1.31 and a beta of 0.66. The firm has a 50-day moving average price of $37.56 and a 200 day moving average price of $40.13. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, January 9th. Investors of record on Friday, November 15th will be issued a dividend of $0.3928 per share. This is an increase from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 annualized dividend and a yield of 4.58%. The ex-dividend date is Friday, November 15th. GSK’s dividend payout ratio (DPR) is currently 99.35%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.